Will the Biden Administration Use ‘March-In’ to Protect Prostate Cancer Patients from Excessive Drug Prices?

>> Read article published STAT

PERI’s Peter Arno and co-authors Robert Sachs and Kathryn Ardizzone support a petition that asks the government to protect U.S. taxpayers from excessive price gouging by Astellas Pharma– a company that makes a prostate cancer drug. The authors propose exercising “march-in rights” for the drug, which would require Health and Human Services to make a modest determination: that it is unreasonable to force Americans to pay three to five times more than people in other high-income countries for a drug developed with U.S. taxpayers’ dollars.